Evgen Pharma (GB:TCF) has released an update.
In a major shift of voting rights, Seneca Partners Limited has reported a decrease from 5.93% to 3.81% in its stake in Theracryf PLC. The notification, dated April 30, 2024, details the change that occurred on April 4, 2024, reflecting the new total of 16,301,456 voting rights held by Seneca Partners. This development could indicate strategic adjustments by the shareholder within the UK-based company.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
